Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

66.7%

2 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

3Total

P 1 (2)

P 2 (1)

Terminated2

Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Showing all 3 trials